Ingrid Burvenich
La Trobe University - ONJCRI Facility Fellow
Ingrid is a senior post-doctoral fellow at the Tumour Targeting Program of Prof Scott, ONJCRI. Dr Burvenich is a highly experienced researcher in molecular imaging and biology, and has extensive experience in animal models of disease, as well as in targeted therapeutics and cancer biology. She also has an extensive experience in large collaborative projects, animal ethics, has an excellent track record in grant success (NHMRC, Philanthropic groups) and in industry engagement. She has been pivotally involved in the preclinical development of bioimaging therapeutic antibodies translating these to Phase I bioimaging studies. In the past five years three of these antibodies have entered phase I bioimaging human trials (NCT01220999, NCT02252211, NCT04297748) and she has been the first author on nine publications.
Related News
Radiotherapy and Theranostics: A Lancet Oncology Commission
The Lancet Oncology Commission Report on Radiotherapy and Theranostics, co-led by Professor Andrew Scott AM, La Trobe University and Olivia Newton-John Cancer Research Institute NIF Node Director, and
07 October 2024
National Imaging Facility granted $28m NCRIS funding to strengthen Australia’s advanced imaging network and bolster health research
The Commonwealth Government Department of Education has today announced National Imaging Facility (NIF) will receive $28m under the National Collaborative Research Infrastructure Strategy (NCRIS), to
19 October 2023
Victorian collaboration raises over $50m investment in critical imaging capabilities
The Victorian Government has invested $14.83m in National Imaging Facility’s (NIF) research infrastructure in Victoria, in partnership with the Victorian Biomedical Imaging Capability (VBIC), equati
04 July 2023
Australian cancer patients to benefit from state-of-the-art ACRF Centre for Precision Medicine at the Olivia Newton-John Cancer Research Institute
A new world-class radiochemistry lab will open at the Olivia Newton-John Cancer Research Institute (ONJCRI) to enable access to innovative cancer therapies for Australians.
18 December 2022